AUS
NZ
UK
CA
USA
IND
Highlights
FTSE 350 pharmaceutical company INDV.L confirms exit from London Stock Exchange
INDV.L to prioritise Nasdaq GS as its sole primary listing moving forward
Majority of INDV.L shareholders and trading activity now based in the United States
FTSE 350-listed pharmaceutical firm (LSE:INDV), which operates within the addiction treatment sector, has announced a complete shift of its primary listing to the Nasdaq Global Select Market (Nasdaq GS). The company, known for developing medications aimed at managing opioid dependency, confirmed that it will no longer maintain its listing on the London Stock Exchange (LSE), citing greater alignment with its business structure and shareholder base in the United States.
INDV.L has been listed on the LSE since its spin-out from a well-known British consumer goods group over a decade ago. However, following its expansion into the US market and the rising volume of trading activity on the Nasdaq GS, the company’s board has opted to consolidate its listing structure.
US-centric operations and shareholder base drive shift
The decision by INDV.L to exit the UK capital market reflects the broader reorientation of its operations toward the United States. The firm stated that a significant share of its revenue now originates from North America, with a notable portion of shareholder trades occurring on Nasdaq GS.
A substantial percentage of the company’s shareholders are now based in the United States, with trading volumes on the Nasdaq GS far exceeding those on the LSE. This shift in trading dynamics has prompted the company to streamline its listing strategy by focusing on a single exchange that aligns more closely with its business activities and shareholder profile.
Recent trend among London-listed firms
The move by INDV.L adds to a series of exits from the London Stock Exchange, with multiple UK-listed firms opting for US markets or private ownership. The trend has resulted in a notable reduction in the number of listed companies on the LSE in recent years. Challenges such as reduced liquidity and fewer new listings have contributed to concerns surrounding the competitiveness of the UK equity market.
According to the company, its listing on Nasdaq GS has delivered greater liquidity, and the consolidation is expected to simplify its capital markets engagement. The Nasdaq GS has been its primary listing since the company transitioned to dual-listed status, and now INDV.L will fully centralise its presence there.
Legacy and product focus
Originally demerged from a major UK-based multinational, INDV.L is recognised for its flagship treatment targeting opioid addiction, a health crisis that has had a lasting impact on North America. Since becoming independent, the firm has grown its US footprint substantially, both in terms of commercial operations and investor engagement.
The company stated that this latest decision reinforces its operational and strategic alignment with the market where it sees the highest level of demand for its products. INDV.L's product portfolio remains focused on medically assisted treatments, and the business continues to operate in a heavily regulated sector.
LSE listing decline continues
The departure of INDV.L underscores broader concerns regarding the competitiveness of the UK capital market. The number of active listings on the LSE has decreased significantly since the global financial downturn, as companies have either delisted or opted to list overseas.
This latest delisting represents another case in a growing list of FTSE firms seeking better market conditions elsewhere. INDV.L's shift away from the LSE is notable, given its long-standing presence and origin within the UK corporate landscape. The company's board emphasised that a sole listing on Nasdaq GS reflects the current profile and geographic focus of its business.
The FTSE 350 pharmaceutical sector continues to evolve as global firms adapt their capital market strategies in response to changing market conditions and investor bases.
